CL2020002519A1 - Composiciones de erenumab y usos de las mismas - Google Patents

Composiciones de erenumab y usos de las mismas

Info

Publication number
CL2020002519A1
CL2020002519A1 CL2020002519A CL2020002519A CL2020002519A1 CL 2020002519 A1 CL2020002519 A1 CL 2020002519A1 CL 2020002519 A CL2020002519 A CL 2020002519A CL 2020002519 A CL2020002519 A CL 2020002519A CL 2020002519 A1 CL2020002519 A1 CL 2020002519A1
Authority
CL
Chile
Prior art keywords
erenumab
compositions
variants
characterization
methods
Prior art date
Application number
CL2020002519A
Other languages
English (en)
Inventor
Kenneth Lawson
Noel Rieder
Suminda Hapuarachchi
Jose Gregorio Ramirez
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2020002519A1 publication Critical patent/CL2020002519A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
    • G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden erenumab y una o más variantes de erenumab, incluyendo variantes de isomerización, variantes de desamidación, variantes ácidas y especies de HMW. También se describen formulaciones farmacéuticas que comprenden las composiciones de erenumab y métodos de uso y caracterización de las composiciones.
CL2020002519A 2018-04-02 2020-09-29 Composiciones de erenumab y usos de las mismas CL2020002519A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02

Publications (1)

Publication Number Publication Date
CL2020002519A1 true CL2020002519A1 (es) 2021-04-05

Family

ID=66248665

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020002519A CL2020002519A1 (es) 2018-04-02 2020-09-29 Composiciones de erenumab y usos de las mismas
CL2023000491A CL2023000491A1 (es) 2018-04-02 2023-02-17 Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000491A CL2023000491A1 (es) 2018-04-02 2023-02-17 Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).

Country Status (19)

Country Link
US (2) US11407838B2 (es)
EP (1) EP3774881A1 (es)
JP (3) JP7840636B2 (es)
KR (1) KR20200139720A (es)
CN (1) CN111954678A (es)
AR (1) AR114722A1 (es)
AU (1) AU2019246983B2 (es)
BR (1) BR112020019882A2 (es)
CA (1) CA3095899A1 (es)
CL (2) CL2020002519A1 (es)
EA (1) EA202092335A1 (es)
IL (1) IL277663A (es)
MA (1) MA52202A (es)
MX (1) MX2020010320A (es)
PH (1) PH12020551618A1 (es)
SA (1) SA520420261B1 (es)
SG (1) SG11202009629YA (es)
TW (1) TWI847980B (es)
WO (1) WO2019195185A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2022232376A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
WO2023120561A1 (ja) * 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント
CN115819589A (zh) * 2022-10-19 2023-03-21 武汉人福创新药物研发中心有限公司 一种培养基及生产抗cgrpr抗体的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2131107T3 (es) 1992-03-17 1999-07-16 Novartis Ag Anticuerpos obtenidos mediante ingenieria genetica.
EP0777684B1 (en) 1994-08-16 2004-04-28 Human Genome Sciences, Inc. Calcitonin receptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
EP1500661A1 (en) 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
CA2461917C (en) 2001-09-27 2012-01-17 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
EA008744B1 (ru) 2002-08-12 2007-08-31 Актавис Груп Хф. Применение соединений антагонистов кальцитонин генсвязанного пептида (cgrp) для лечения псориаза
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
AU2005310305A1 (en) 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
AU2005299716B2 (en) 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
EP2064244B1 (en) 2006-08-03 2019-06-05 MedImmune Limited ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
WO2009109908A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating inflammatory pain
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
CN102281901A (zh) * 2008-11-20 2011-12-14 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AU2010221156A1 (en) * 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US20120177640A1 (en) * 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
ES2982297T3 (es) 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
SG10201605397PA (en) 2011-07-01 2016-08-30 Hoffmann La Roche Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
CA2857194A1 (en) * 2011-12-07 2013-06-13 Thomas M. Dillon Igg2 disulfide isoform separation
JP6092892B2 (ja) * 2011-12-15 2017-03-08 プレステージ バイオファーマ プライベート リミテッド 抗体の精製方法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
CA2906737C (en) 2013-03-15 2023-08-15 Amgen Inc. Human pac1 antibodies
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
AU2014287044B2 (en) * 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI799849B (zh) * 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp

Also Published As

Publication number Publication date
PH12020551618A1 (en) 2021-08-16
MA52202A (fr) 2021-02-17
MX2020010320A (es) 2021-01-08
JP2021519790A (ja) 2021-08-12
TWI847980B (zh) 2024-07-11
IL277663A (en) 2020-11-30
AU2019246983B2 (en) 2025-12-18
US11407838B2 (en) 2022-08-09
JP2026034591A (ja) 2026-02-27
KR20200139720A (ko) 2020-12-14
WO2019195185A1 (en) 2019-10-10
SA520420261B1 (ar) 2024-05-23
EA202092335A1 (ru) 2021-01-22
SG11202009629YA (en) 2020-10-29
EP3774881A1 (en) 2021-02-17
CL2023000491A1 (es) 2023-10-13
CA3095899A1 (en) 2019-10-10
AU2019246983A1 (en) 2020-10-29
BR112020019882A2 (pt) 2021-01-05
JP7840636B2 (ja) 2026-04-06
TW202003572A (zh) 2020-01-16
US20190300617A1 (en) 2019-10-03
JP2023103323A (ja) 2023-07-26
CN111954678A (zh) 2020-11-17
AR114722A1 (es) 2020-10-07
US20220348673A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
SV2018005643A (es) Composiciones de insulina de rapida accion
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MX2020001885A (es) Formulaciones de daptomicina.
BR112018013761A2 (pt) compostos antiproliferativos e suas composições farmacêuticas e usos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX391757B (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
MX2020008125A (es) Composiciones que comprenden berberina.
ZA202102816B (en) High concentration protein formulation
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112022010143A2 (pt) Inibidores de ahr e usos respectivos
MX2018009364A (es) Sal de succinato de citisina y uso de la misma.
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.
EA202191345A1 (ru) Стабильный состав глюкокортикоидов